ContextVision, a global leader in medical imaging software, and AMRA Medical
(Sweden), a pioneer in magnetic resonance imaging (MRI) based body composition
analysis, today announce a research partnership focused on advancing the
diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD).

The collaboration expands upon ContextVision's ongoing Data Quality initiative
to develop AI-powered, organ-specific imaging solutions that enable MASLD
screening and physiological quantification. The joint effort builds on
ContextVision's strategic clinical partnership with the University of Washington
(USA), where a clinical evaluation is underway to acquire imaging data for the
development of a multiparameter biomarker for MASLD. AMRA Medical now joins this
effort by adding their MRI-based analysis for measuring liver fat (PDFF),
abdominal fat volumes, and detailed muscle assessment. AMRAs contribution will
further enrich  the multimodal dataset by enabling correlations between MRI and
ultrasound imaging biomarkers thereby strengthening ContextVision's development
of disease staging solutions.

Combining strengths to advance liver diagnostics

"As we build out our Data Quality business, partnerships like this are
essential," said Gerald Pötzsch, CEO of ContextVision. "AMRA's highly detailed
MRI measurements, add critical value to our clinical data pipeline. Together, we
are moving closer to a new standard in liver disease diagnostics - non-invasive,
accurate, and scalable."

Olof Dahlqvist Leinhard, CEO of AMRA Medical, stated: "We're excited to join
ContextVision's broader initiative to redefine liver diagnostics. Our combined
technologies offer a more complete and individualized picture of patient
health."

The collaboration supports ContextVision's growing list of global partners that
already includes ultrasound imaging research from the University of Waterloo's
LITMUS Lab (Canada) and R&D support from InPhase Solutions AS (Norway).
Together, these partnerships underpin the expertise needed to discover and
develop a robust, AI-powered diagnostic platform for MALD - grounded in imaging
physics, clinical relevance, as well as high-quality multimodal data.

Meeting a global need for earlier, smarter liver diagnostics

MASLD affects approximately one in four people globally and is rapidly becoming
one of the leading causes of chronic liver disease. The need for non-invasive,
cost-effective diagnostic solutions is urgent - particularly as current methods
often miss early stages of disease. By integrating MRI and ultrasound
technologies through this partnership, ContextVision and AMRA Medical aim to
deliver actionable, multimodal biomarkers to improve early detection and
treatment planning for millions of patients.

For more information, please contact
Gerald Pötzsch
Chief Executive Officer, ContextVision
gerald.potzsch@contextvision.com

About ContextVision
ContextVision is a software company specialized in image analysis and artificial
intelligence. As the global market leader within image enhancement, we are a
trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment
around the world. Our expertise is to develop powerful software products, based
on proprietary technology and artificial intelligence for image-based
applications. Our cutting-edge technology helps clinicians accurately interpret
medical images, a crucial foundation for better diagnosis and treatment. The
company, established in 1983, is based in Sweden with local representation in
the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock
Exchange under the ticker CONTX.

About AMRA Medical
AMRA Medical (http://www.amramedical.com/) is a health informatics and precision
medicine company that is pioneering body composition analysis, providing cutting
-edge solutions to advance both clinical research and patient care initiatives.
AMRA's gold-standard technology delivers multiple fat and muscle biomarkers -
derived simply from rapid whole-body MRI scans. AMRA is committed to driving
transformative care and simplifying vital decision-making in both research and
clinical care settings by offering support services via their innovative
platform.